YHB Investment Advisors Inc. grew its holdings in shares of Celgene Co. (NASDAQ:CELG) by 10.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 82,332 shares of the biopharmaceutical company’s stock after acquiring an additional 7,777 shares during the period. Celgene comprises about 1.5% of YHB Investment Advisors Inc.’s investment portfolio, making the stock its 19th biggest holding. YHB Investment Advisors Inc.’s holdings in Celgene were worth $8,592,000 at the end of the most recent quarter.
Several other institutional investors have also made changes to their positions in the company. Janus Henderson Group PLC grew its stake in Celgene by 4,290.5% in the second quarter. Janus Henderson Group PLC now owns 8,408,961 shares of the biopharmaceutical company’s stock worth $1,092,071,000 after purchasing an additional 8,217,433 shares in the last quarter. BlackRock Inc. grew its stake in Celgene by 5.7% in the second quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock worth $7,366,919,000 after purchasing an additional 3,084,227 shares in the last quarter. Oaktop Capital Management II L.P. acquired a new position in Celgene in the second quarter worth about $271,605,000. Arrowstreet Capital Limited Partnership grew its stake in Celgene by 1,489.2% in the second quarter. Arrowstreet Capital Limited Partnership now owns 1,907,052 shares of the biopharmaceutical company’s stock worth $247,669,000 after purchasing an additional 1,787,052 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in Celgene by 3.1% in the second quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock worth $6,951,579,000 after purchasing an additional 1,610,056 shares in the last quarter. Institutional investors own 78.10% of the company’s stock.
In other news, insider Mark J. Alles bought 3,260 shares of the company’s stock in a transaction that occurred on Thursday, February 8th. The shares were purchased at an average price of $91.90 per share, with a total value of $299,594.00. Following the completion of the acquisition, the insider now directly owns 178,904 shares in the company, valued at $16,441,277.60. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.95% of the stock is owned by insiders.
A number of research firms recently commented on CELG. Vetr upgraded Celgene from a “buy” rating to a “strong-buy” rating and set a $116.84 price target for the company in a research note on Thursday, January 25th. Mizuho set a $128.00 price target on Celgene and gave the stock a “buy” rating in a research note on Tuesday, December 26th. William Blair reiterated an “outperform” rating on shares of Celgene in a research note on Friday, October 20th. BTIG Research reiterated a “hold” rating on shares of Celgene in a research note on Tuesday, January 23rd. Finally, BidaskClub upgraded Celgene from a “sell” rating to a “hold” rating in a research note on Tuesday, December 12th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, eighteen have issued a buy rating and two have issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $130.35.
Shares of Celgene Co. (NASDAQ CELG) opened at $91.98 on Wednesday. Celgene Co. has a twelve month low of $88.32 and a twelve month high of $147.17. The company has a market capitalization of $68,831.59, a P/E ratio of 25.69, a P/E/G ratio of 0.64 and a beta of 1.49. The company has a current ratio of 4.99, a quick ratio of 4.80 and a debt-to-equity ratio of 2.29.
Celgene (NASDAQ:CELG) last announced its earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.78 by $0.09. Celgene had a return on equity of 67.50% and a net margin of 22.38%. The firm had revenue of $3.48 billion for the quarter, compared to analysts’ expectations of $3.46 billion. During the same quarter in the previous year, the company earned $1.61 earnings per share. The firm’s quarterly revenue was up 16.9% compared to the same quarter last year. analysts expect that Celgene Co. will post 7.68 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This article was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.dispatchtribunal.com/2018/02/14/celgene-co-celg-stake-increased-by-yhb-investment-advisors-inc.html.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.